RU2007141625A - Вариантные формы уратоксидазы и их применение - Google Patents
Вариантные формы уратоксидазы и их применение Download PDFInfo
- Publication number
- RU2007141625A RU2007141625A RU2007141625/13A RU2007141625A RU2007141625A RU 2007141625 A RU2007141625 A RU 2007141625A RU 2007141625/13 A RU2007141625/13 A RU 2007141625/13A RU 2007141625 A RU2007141625 A RU 2007141625A RU 2007141625 A RU2007141625 A RU 2007141625A
- Authority
- RU
- Russia
- Prior art keywords
- uricase
- nucleic acid
- conjugate
- polyethylene glycol
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Изолированная укороченная уриказа млекопитающего, содержащая аминокислотную последовательность уриказы млекопитающего, укороченную с аминоконца или карбоксиконца или и с амино- и с карбоксиконца приблизительно на 1-13 аминокислот и дополнительно содержащая аминокислотную замену приблизительно в положении 46. ! 2. Уриказа по п.1, дополнительно содержащая аминоконцевую аминокислоту, где данной аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин. ! 3. Уриказа по п.2, где аминоконцевой аминокислотой является треонин. ! 4. Уриказа по п.1, где заменой является замена на треонин или аланин. ! 5. Уриказа по п.3, где заменой является замена на треонин. ! 6. Уриказа по п.5, содержащая аминокислотную последовательность SEQ ID № 8. ! 7. Уриказа по любому из пп.1-6, где уриказа конъюгирована с полимером. ! 8. Конъюгат полиэтиленгликоль-уриказа, содержащий уриказу по любому из пп.1-6. ! 9. Конъюгат по п.8, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы. ! 10. Конъюгат по п.9, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы. ! 11. Конъюгат по п.8, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 100 кД. ! 12. Конъюгат по п.11, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 50 кД. ! 13. Конъюгат по п.12, где каждая молекула полиэтиленгликоля имела молекулярную массу от 5 кД до 20 кД. ! 14. Конъюгат по п.13, где каждая молекула полиэтиленгликоля имела молекулярную массу приблизительно 10 кД. ! 15. Фармацевтическая композиция, содержащая уриказу по любому из пп.1-5. ! 16. Фармацевтическая композиция, содержащая конъюгат по п.8. ! 17. Композиция по п.15, при
Claims (37)
1. Изолированная укороченная уриказа млекопитающего, содержащая аминокислотную последовательность уриказы млекопитающего, укороченную с аминоконца или карбоксиконца или и с амино- и с карбоксиконца приблизительно на 1-13 аминокислот и дополнительно содержащая аминокислотную замену приблизительно в положении 46.
2. Уриказа по п.1, дополнительно содержащая аминоконцевую аминокислоту, где данной аминоконцевой аминокислотой является аланин, глицин, пролин, серин или треонин.
3. Уриказа по п.2, где аминоконцевой аминокислотой является треонин.
4. Уриказа по п.1, где заменой является замена на треонин или аланин.
5. Уриказа по п.3, где заменой является замена на треонин.
6. Уриказа по п.5, содержащая аминокислотную последовательность SEQ ID № 8.
7. Уриказа по любому из пп.1-6, где уриказа конъюгирована с полимером.
8. Конъюгат полиэтиленгликоль-уриказа, содержащий уриказу по любому из пп.1-6.
9. Конъюгат по п.8, содержащий от 2 до 12 молекул полиэтиленгликоля на каждую субъединицу уриказы.
10. Конъюгат по п.9, содержащий от 3 до 10 молекул полиэтиленгликоля на каждую субъединицу уриказы.
11. Конъюгат по п.8, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 100 кД.
12. Конъюгат по п.11, где каждая молекула полиэтиленгликоля имела молекулярную массу от 1 кД до 50 кД.
13. Конъюгат по п.12, где каждая молекула полиэтиленгликоля имела молекулярную массу от 5 кД до 20 кД.
14. Конъюгат по п.13, где каждая молекула полиэтиленгликоля имела молекулярную массу приблизительно 10 кД.
15. Фармацевтическая композиция, содержащая уриказу по любому из пп.1-5.
16. Фармацевтическая композиция, содержащая конъюгат по п.8.
17. Композиция по п.15, пригодная для повторного введения.
18. Композиция по п.16, пригодная для повторного введения.
19. Способ снижения уровней мочевой кислоты в биологической жидкости организма нуждающегося в этом пациента, включающий введение в организм пациента композиции по п.15.
20. Способ снижения уровней мочевой кислоты в биологической жидкости организма нуждающегося в этом пациента, включающий введение в организм пациента композиции по п.16.
21. Способ по п.19, где данной биологической жидкостью является кровь.
22. Способ по п.20, где данной биологической жидкостью является кровь.
23. Изолированная уриказа, содержащая аминокислотную последовательность SEQ ID № 14.
24. Изолированный укороченный белок уриказы млекопитающего по п.1, где N-концевой аминокислотой является метионин.
25. Уриказа по п.24, содержащая аминокислотную последовательность SEQ ID № 7.
26. Изолированная нуклеиновая кислота, содержащая последовательность нуклеиновой кислоты, кодирующей белок по пп.1, 3, 6, 24 или 25.
27. Изолированная нуклеиновая кислота по п.26, где последовательность нуклеиновой кислоты функционально связана с гетерологичным промотором.
28. Нуклеиновая кислота по п.27, где промотором является промотор osmB.
29. Вектор нуклеиновой кислоты, содержащий нуклеиновую кислоту по п.27.
30. Клетка-хозян, содержащая вектор по п.29.
31. Изолированная нуклеиновая кислота, содержащая последовательность нуклеиновой кислоты, кодирующую уриказу, содержащую аминокислотную последовательность SEQ ID № 7 или SEQ ID № 8.
32. Изолированная нуклеиновая кислота по п.31, где последовательность нуклеиновой кислоты содержит SEQ ID № 9 или SEQ ID № 10.
33. Изолированная нуклеиновая кислота по п.31, где последовательность нуклеиновой кислоты функционально связана с гетерологичным промотором.
34. Нуклеиновая кислота по п.33, где данным промотором является промотор osmB.
35. Вектор нуклеиновой кислоты, содержащий нуклеиновую кислоту по п.33.
36. Клетка-хозян, содержащая вектор по п.35.
37. Способ получения уриказы, включающий стадии культивирования клетки-хозяина по п.30 или 36 в таких условиях, при которых последовательность нуклеиновой кислоты экспрессируется клеткой-хозяином, и выделения экспрессированной уриказы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67057305P | 2005-04-11 | 2005-04-11 | |
US60/670,573 | 2005-04-11 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012106150/10A Division RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106116A Division RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106148/10A Division RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007141625A true RU2007141625A (ru) | 2009-05-20 |
RU2451074C2 RU2451074C2 (ru) | 2012-05-20 |
Family
ID=37075495
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007141625/10A RU2451074C2 (ru) | 2005-04-11 | 2006-04-11 | Вариантные формы уратоксидазы и их применение |
RU2012106116A RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012106116A RU2610680C9 (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106150/10A RU2012106150A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
RU2012106148/10A RU2012106148A (ru) | 2005-04-11 | 2012-02-20 | Вариантные формы уратоксидазы и их применение |
Country Status (27)
Country | Link |
---|---|
US (12) | US8188224B2 (ru) |
EP (3) | EP3321359B1 (ru) |
JP (6) | JP2008535500A (ru) |
KR (1) | KR20080009111A (ru) |
CN (1) | CN101198693B (ru) |
AU (1) | AU2006235495B2 (ru) |
BR (1) | BRPI0612941A2 (ru) |
CA (1) | CA2604399A1 (ru) |
CY (1) | CY1124138T1 (ru) |
CZ (1) | CZ2007695A3 (ru) |
DK (1) | DK3321359T3 (ru) |
ES (2) | ES2538357T3 (ru) |
FR (1) | FR15C0067I2 (ru) |
HK (1) | HK1112021A1 (ru) |
HU (2) | HU229068B1 (ru) |
IL (1) | IL186510A (ru) |
LT (1) | LT3321359T (ru) |
MX (1) | MX2007012547A (ru) |
NZ (1) | NZ562292A (ru) |
PL (2) | PL215285B1 (ru) |
PT (1) | PT3321359T (ru) |
RU (4) | RU2451074C2 (ru) |
SG (1) | SG161247A1 (ru) |
SI (1) | SI3321359T1 (ru) |
TW (1) | TWI366467B (ru) |
WO (1) | WO2006110819A2 (ru) |
ZA (1) | ZA200708650B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2338665C (en) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
US8148123B2 (en) * | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
US20080159976A1 (en) * | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
SG2014009484A (en) * | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
ES2532804T3 (es) * | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
CN102051348B (zh) * | 2009-10-27 | 2012-10-03 | 重庆富进生物医药有限公司 | 人源化重组尿酸酶及其突变体 |
WO2011127393A2 (en) | 2010-04-08 | 2011-10-13 | Georgia Tech Research Corporation | Variants of ancestral uricases and uses thereof |
CN102634492B (zh) * | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
CN102260653B (zh) * | 2011-06-30 | 2013-04-03 | 荣俊 | 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法 |
CN103834623B (zh) * | 2014-02-11 | 2017-11-07 | 中国药科大学 | 具有催化活性的人源尿酸氧化酶 |
SG10201910522TA (en) * | 2015-05-15 | 2020-01-30 | Medimmune Llc | Improved uricase sequences and methods of treatment |
US20230085022A1 (en) * | 2016-11-11 | 2023-03-16 | Horizon Therapeutics Usa, Inc. | Combination therapies of prednisone and uricase molecules and uses thereof |
KR20220004145A (ko) * | 2019-05-10 | 2022-01-11 | 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) | 폴리에틸렌 글리콜로 변형된 요산 산화효소 |
WO2021042055A1 (en) * | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
CN112980808A (zh) * | 2019-12-12 | 2021-06-18 | 深圳迈瑞生物医疗电子股份有限公司 | 尿酸酶、及其制备方法和用途 |
CN113144174B (zh) * | 2020-01-22 | 2023-07-04 | 杭州远大生物制药有限公司 | 治疗高尿酸相关性疾病的药物 |
EP4240423A1 (en) | 2020-11-03 | 2023-09-13 | Protalix Ltd. | Modified uricase and uses thereof |
CN114438048A (zh) * | 2020-11-05 | 2022-05-06 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
CN114438047A (zh) * | 2020-11-05 | 2022-05-06 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
WO2022214086A1 (zh) * | 2021-04-09 | 2022-10-13 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
CN117230034A (zh) * | 2023-10-16 | 2023-12-15 | 临沂大学 | 一种高稳定性哺乳动物尿酸氧化酶突变体 |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE279489C (ru) | ||||
DE279486C (ru) | ||||
US1141973A (en) | 1911-05-22 | 1915-06-08 | Jesse W Nichols | Can-cap with vent-shield. |
DE837379C (de) | 1950-04-20 | 1955-08-16 | Nordwind G M B H | Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe |
US3451996A (en) | 1968-02-12 | 1969-06-24 | Thompson Farms Co | Method for the preparation of heparin |
US3616231A (en) | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
US3613231A (en) | 1969-07-25 | 1971-10-19 | Paul F Pugh | Method for manufacturing high voltage cable systems |
US3931399A (en) | 1970-12-22 | 1976-01-06 | Behringwerke Aktiengesellschaft | Process for isolating a fibrin-stabilizing factor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4027676A (en) | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
US4169764A (en) | 1975-08-13 | 1979-10-02 | Ajinomoto Co., Inc. | Process for production of urokinase |
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US4064010A (en) | 1976-07-21 | 1977-12-20 | Eastman Kodak Company | Purification of uricase |
US4301153A (en) | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
US4425431A (en) | 1978-04-20 | 1984-01-10 | Toyo Soda Manufacturing Co., Ltd. | Production of an allose-containing polysaccharide |
US4312979A (en) | 1978-04-20 | 1982-01-26 | Toyo Soda Manufacturing Co., Ltd. | Polysaccharides containing allose |
JPS6031472B2 (ja) | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
US4251431A (en) | 1979-01-16 | 1981-02-17 | Shell Oil Company | Lubricating greases |
JPS5599189A (en) | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
JPS55135590A (en) | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
DE2943016C2 (de) | 1979-10-24 | 1984-09-06 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Verfahren zur Reinigung von Interferon |
JPS5651995A (en) | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
DE3005897A1 (de) | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
FR2475900A1 (fr) | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
CH651308A5 (de) | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
JPS5740503A (en) | 1980-08-22 | 1982-03-06 | Seikagaku Kogyo Co Ltd | Separation of saccharides |
US4315852A (en) | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
FR2497006A1 (fr) | 1980-12-24 | 1982-06-25 | Ind Electro Ste Gle | Contacts electriques pour cables coaxiaux et cables bifilaires |
JPS57192435A (en) | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
DE3126759A1 (de) | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung |
US4450103A (en) | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
US4485176A (en) | 1982-06-28 | 1984-11-27 | E. I. Du Pont De Nemours & Company | Turbidimetric method for measuring protein in urine and cerebrospinal fluid |
EP0109688A3 (en) | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Improved complexes, processes for obtaining them and formulations containing such complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
USD279486S (en) | 1983-04-25 | 1985-07-02 | International Jensen Incorporated | Controller for a video game or the like |
US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
JPH0671425B2 (ja) | 1985-06-05 | 1994-09-14 | サッポロビール株式会社 | ウリカ−ゼおよびその製造法 |
JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
AU597924B2 (en) | 1985-12-11 | 1990-06-14 | Natinco Nv | Solubilization of protein aggregates |
DD279486A1 (de) | 1986-03-10 | 1990-06-06 | Akad Wissenschaften Ddr | Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JPS6255079A (ja) | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DD279489A1 (de) | 1986-12-11 | 1990-06-06 | Leuna Werke Veb | Verfahren zur herstellung optisch transparenter epoxidharzformmassen |
JPS63203548A (ja) | 1987-02-12 | 1988-08-23 | 四国化工機株式会社 | 飲料用密封容器の製造装置 |
AU612133B2 (en) | 1987-02-20 | 1991-07-04 | Natinco Nv | Production of proteins in active forms |
CA1305285C (en) | 1987-04-21 | 1992-07-14 | Malcolm Roy Brandon | Production of proteins in active forms |
AU609824B2 (en) | 1987-06-15 | 1991-05-09 | Southern Cross Biotech Pty Ltd. | Production of proteins in active forms |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
CA1286591C (en) | 1987-12-18 | 1991-07-23 | Douglas B. Taylor | Apparatus for opening and closing roll-up door |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
JPH01216939A (ja) | 1988-02-24 | 1989-08-30 | Hoechst Japan Kk | 末熟児頭蓋内出血阻止剤 |
US4945086A (en) | 1988-05-03 | 1990-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Smooth muscle cell growth inhibitor |
US5955336A (en) | 1988-08-17 | 1999-09-21 | Toyo Boseki Kabushiki Kaisha | DNA sequence for uricase and manufacturing process of uricase |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
JP3148208B2 (ja) | 1988-10-31 | 2001-03-19 | 富士ゼロックス株式会社 | マルチ出力トレイ付プリントサーバおよびプリントシステム |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
US5382518A (en) | 1989-07-13 | 1995-01-17 | Sanofi | Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells |
NZ234453A (en) | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
JPH0354581A (ja) | 1989-07-24 | 1991-03-08 | Nec Corp | 電子写真系プリンタの現像カートリッジ |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
AU654804B2 (en) | 1989-08-23 | 1994-11-24 | Zvi Fuks | Wound healing preparations containing heparanase |
JPH03148298A (ja) | 1989-11-01 | 1991-06-25 | Sumitomo Pharmaceut Co Ltd | 修飾ペプチドおよびその製造方法 |
JPH03148208A (ja) | 1989-11-02 | 1991-06-25 | Mikimoto Seiyaku Kk | 皮膚外用剤 |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
KR100246082B1 (ko) | 1991-07-02 | 2000-04-01 | 인헤일, 인코오포레이티드 | 에어로졸화된약제를전달하는방법및장치 |
YU66892A (sh) | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
JP3148298B2 (ja) | 1991-09-02 | 2001-03-19 | 帝人株式会社 | 軽量複合成形物の製造法 |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
AU6240494A (en) | 1993-02-16 | 1994-09-14 | Enzon, Inc. | Ribosome inactivating protein compositions having reduced antigenicity |
JP3875730B2 (ja) | 1993-02-22 | 2007-01-31 | サノフィ・アベンティス株式会社 | 自己免疫疾患の予防治療剤 |
US6385312B1 (en) | 1993-02-22 | 2002-05-07 | Murex Securities, Ltd. | Automatic routing and information system for telephonic services |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
JPH06255079A (ja) | 1993-03-08 | 1994-09-13 | Akira Totsuka | 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法 |
US5863534A (en) | 1993-04-09 | 1999-01-26 | Bio-Technology General Corp. | Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity |
CA2159218A1 (en) | 1993-04-09 | 1994-10-27 | Elisha P. Zeelon | Novel polypeptide having factor xa inhibitory activity |
AU6586394A (en) | 1993-04-22 | 1994-11-08 | Celtrix Pharmaceuticals, Inc. | Conjugates of growth factor and bone resorption inhibitor |
AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
WO1995011987A1 (en) | 1993-10-29 | 1995-05-04 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
AU691225B2 (en) | 1993-11-10 | 1998-05-14 | Schering Corporation | Improved interferon polymer conjugates |
US5795776A (en) | 1994-03-22 | 1998-08-18 | Bio-Technology General Corp. | Expression plasmids regulated by an OSMB promoter |
FI96317C (fi) | 1994-05-31 | 1996-06-10 | Exavena Oy | Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi |
DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996017929A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
IL116696A (en) | 1995-01-25 | 1999-08-17 | Bio Technology General Corp | Production of enzymatically active recombinant carboxypeptidase b |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
FR2733914B1 (fr) | 1995-05-11 | 1997-08-01 | Sanofi Sa | Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation |
JPH09154581A (ja) | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
DK1007082T3 (da) | 1997-01-15 | 2007-02-19 | Phoenix Pharmacologics Inc | Modificeret tumor nekrose faktor |
US5816397A (en) | 1997-01-21 | 1998-10-06 | Ogio International, Inc. | Golf club carrying apparatus |
JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして/又は除去された付着基を有するポリペプチド−ポリマー結合体 |
KR100369838B1 (ko) | 1997-02-26 | 2003-09-29 | 주식회사 엘지생명과학 | 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법 |
US6821763B2 (en) | 1997-07-04 | 2004-11-23 | Ajinomoto Co., Inc. | Process for producing microbial transglutaminase |
JPH1175876A (ja) * | 1997-07-04 | 1999-03-23 | Ajinomoto Co Inc | 新規な微生物トランスグルタミナーゼの製造法 |
IL139609A (en) | 1998-06-01 | 2006-06-11 | Genentech Inc | Separation of polypeptides monomers |
ATE483797T1 (de) * | 1998-08-06 | 2010-10-15 | Univ Duke | Harnsäureoxidase |
HU226294B1 (en) | 1998-08-06 | 2008-08-28 | Mountain View Pharmaceuticals | Peg-urate oxidase conjugates and use thereof |
US20060188971A1 (en) | 1998-08-06 | 2006-08-24 | Duke University | Urate oxidase |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
CA2338665C (en) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
KR19980069019U (ko) | 1998-09-29 | 1998-12-05 | 양영석 | 신축성 핸드폰 케이스 |
US6425448B1 (en) | 2001-01-30 | 2002-07-30 | Cdx Gas, L.L.P. | Method and system for accessing subterranean zones from a limited surface area |
US6429860B1 (en) | 1999-06-15 | 2002-08-06 | Visicomp, Inc. | Method and system for run-time visualization of the function and operation of a computer program |
BR0108783A (pt) | 2000-02-14 | 2005-04-05 | First Opinion Corp | Esquema de dados para o diagnóstico de uma doença, método de diagnóstico automatizado, método de diagnóstico computadorizado, método para a reutilização de objetos de roteiros médicos utilizados no diagnóstico automatizado ou no gerenciamento de uma condição médica e sistema de diagnóstico automatizado |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US20050084478A1 (en) | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US20020168360A1 (en) | 2001-03-02 | 2002-11-14 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
WO2003045436A1 (en) | 2001-11-28 | 2003-06-05 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
ATE364092T1 (de) | 2003-01-09 | 2007-06-15 | Genentech Inc | Reinigung von polypeptiden |
JP4273998B2 (ja) | 2004-02-26 | 2009-06-03 | 学校法人東海大学 | プロテオーム解析用試料の調製方法 |
US20050282877A1 (en) | 2004-04-13 | 2005-12-22 | Becker Bryan N | Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers |
WO2006017206A2 (en) | 2004-07-12 | 2006-02-16 | Tengen Biomedical Company | Flavivirus vaccine |
GB0420888D0 (en) | 2004-09-20 | 2004-10-20 | Photopharmica Ltd | Compounds and uses |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
SG2014009484A (en) * | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
US20080159976A1 (en) | 2005-04-11 | 2008-07-03 | Jacob Hartman | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
MX2008010806A (es) | 2006-02-22 | 2008-09-01 | Novartis Pharma Ag | Sistema para la administracion de ciclosporina nebulizada y metodos de tratamiento. |
ES2532804T3 (es) | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
NL1031926C2 (nl) | 2006-05-31 | 2007-12-03 | X Flow Bv | Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum. |
WO2008063663A2 (en) | 2006-11-21 | 2008-05-29 | University Of Southern California | Poly (ethylene glycol) anti-body detection assays and kits for performing thereof |
WO2009048148A1 (ja) | 2007-10-10 | 2009-04-16 | Kyowa Hakko Bio Co., Ltd. | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 |
CN101168052A (zh) | 2007-10-26 | 2008-04-30 | 西安交通大学 | 一种防治高尿酸血症及痛风的肠溶制剂 |
TW201016208A (en) | 2008-09-15 | 2010-05-01 | Elan Pharm Inc | Methods of treatment of hyperuricemia and associated disease states |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
JP5451464B2 (ja) | 2010-03-09 | 2014-03-26 | キヤノン株式会社 | 帯電装置 |
US9402827B2 (en) | 2010-03-30 | 2016-08-02 | Ardea Biosciences, Inc. | Treatment of gout |
WO2013066353A1 (en) | 2011-11-04 | 2013-05-10 | Metabolex, Inc. | Methods for treating gout flares |
JP5746101B2 (ja) | 2012-06-18 | 2015-07-08 | コスメディ製薬株式会社 | マイクロニードルの迅速溶解法 |
GB2512876A (en) | 2013-04-09 | 2014-10-15 | Image Analysis Ltd | Methods and apparatus for quantifying inflammation |
MD4779B1 (ru) | 2014-04-04 | 2021-12-31 | Pfizer Inc. | Бициклические конденсированные арильные или гетероарильные соединения и их применение в качестве ингибиторов IRAK4 |
CA3017365A1 (en) | 2016-03-11 | 2017-09-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
US20180008665A1 (en) | 2016-07-05 | 2018-01-11 | CanTrust LifeScience Corp. | Methods of treating and preventing gout and lead nephropathy |
US20220409620A1 (en) | 2016-11-11 | 2022-12-29 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
US20230085022A1 (en) | 2016-11-11 | 2023-03-16 | Horizon Therapeutics Usa, Inc. | Combination therapies of prednisone and uricase molecules and uses thereof |
US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
EP3592389A1 (en) | 2017-03-11 | 2020-01-15 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
WO2020160324A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
US20200237879A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
WO2021042055A1 (en) | 2019-08-30 | 2021-03-04 | Horizon Pharma Rheumatology Llc | Pegloticase for treatment of gout in renal transplant recipients |
JP2023537403A (ja) | 2020-08-10 | 2023-08-31 | ホライゾン セラピューティクス ユーエスエー インコーポレイテッド | 痛風を治療する方法 |
-
2006
- 2006-04-11 ES ES06749889.9T patent/ES2538357T3/es active Active
- 2006-04-11 KR KR20077026113A patent/KR20080009111A/ko active Search and Examination
- 2006-04-11 HU HU0700730A patent/HU229068B1/hu active Protection Beyond IP Right Term
- 2006-04-11 MX MX2007012547A patent/MX2007012547A/es active IP Right Grant
- 2006-04-11 ES ES17192971T patent/ES2856881T3/es active Active
- 2006-04-11 RU RU2007141625/10A patent/RU2451074C2/ru not_active IP Right Cessation
- 2006-04-11 JP JP2008505664A patent/JP2008535500A/ja active Pending
- 2006-04-11 NZ NZ562292A patent/NZ562292A/en not_active IP Right Cessation
- 2006-04-11 PT PT171929714T patent/PT3321359T/pt unknown
- 2006-04-11 CZ CZ20070695A patent/CZ2007695A3/cs unknown
- 2006-04-11 PL PL387691A patent/PL215285B1/pl unknown
- 2006-04-11 EP EP17192971.4A patent/EP3321359B1/en active Active
- 2006-04-11 LT LTEP17192971.4T patent/LT3321359T/lt unknown
- 2006-04-11 AU AU2006235495A patent/AU2006235495B2/en active Active
- 2006-04-11 CN CN2006800210183A patent/CN101198693B/zh active Active
- 2006-04-11 DK DK17192971.4T patent/DK3321359T3/da active
- 2006-04-11 TW TW095112937A patent/TWI366467B/zh active
- 2006-04-11 HU HUE17192971A patent/HUE052976T2/hu unknown
- 2006-04-11 PL PL17192971T patent/PL3321359T3/pl unknown
- 2006-04-11 EP EP15156612.2A patent/EP2947145A1/en not_active Withdrawn
- 2006-04-11 CA CA 2604399 patent/CA2604399A1/en not_active Abandoned
- 2006-04-11 WO PCT/US2006/013660 patent/WO2006110819A2/en active Search and Examination
- 2006-04-11 SG SG201002407-3A patent/SG161247A1/en unknown
- 2006-04-11 SI SI200632400T patent/SI3321359T1/sl unknown
- 2006-04-11 US US11/918,297 patent/US8188224B2/en active Active
- 2006-04-11 BR BRPI0612941-2A patent/BRPI0612941A2/pt not_active Application Discontinuation
- 2006-04-11 EP EP20060749889 patent/EP1871874B1/en active Active
-
2007
- 2007-10-09 IL IL186510A patent/IL186510A/en active IP Right Grant
- 2007-10-10 ZA ZA200708650A patent/ZA200708650B/xx unknown
-
2008
- 2008-06-19 HK HK08106827.8A patent/HK1112021A1/xx unknown
-
2012
- 2012-02-20 RU RU2012106116A patent/RU2610680C9/ru not_active IP Right Cessation
- 2012-02-20 RU RU2012106150/10A patent/RU2012106150A/ru not_active Application Discontinuation
- 2012-02-20 RU RU2012106148/10A patent/RU2012106148A/ru not_active Application Discontinuation
- 2012-05-01 US US13/461,170 patent/US8541205B2/en active Active
-
2013
- 2013-01-23 JP JP2013009968A patent/JP2013135676A/ja not_active Withdrawn
- 2013-08-21 US US13/972,167 patent/US9017980B2/en active Active
-
2015
- 2015-01-07 JP JP2015001805A patent/JP2015107122A/ja active Pending
- 2015-03-27 US US14/671,246 patent/US9670467B2/en active Active
- 2015-10-07 FR FR15C0067C patent/FR15C0067I2/fr active Active
-
2016
- 2016-07-04 JP JP2016132216A patent/JP2016171819A/ja not_active Withdrawn
-
2017
- 2017-04-18 US US15/490,736 patent/US20170298326A1/en not_active Abandoned
- 2017-07-13 US US15/649,398 patent/US20170313993A1/en not_active Abandoned
- 2017-07-13 US US15/649,462 patent/US9926537B2/en active Active
- 2017-07-13 US US15/649,478 patent/US10160958B2/en active Active
- 2017-07-13 US US15/649,488 patent/US9926538B2/en active Active
- 2017-10-18 JP JP2017201898A patent/JP2018015005A/ja active Pending
-
2018
- 2018-11-28 US US16/202,743 patent/US10731139B2/en active Active
-
2019
- 2019-01-04 JP JP2019000199A patent/JP2019070006A/ja active Pending
-
2020
- 2020-06-24 US US16/911,074 patent/US11345899B2/en active Active
-
2021
- 2021-03-02 CY CY20211100173T patent/CY1124138T1/el unknown
-
2022
- 2022-04-19 US US17/724,091 patent/US11781119B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007141625A (ru) | Вариантные формы уратоксидазы и их применение | |
Hwang et al. | Cell adhesion biomaterial based on mussel adhesive protein fused with RGD peptide | |
US6235716B1 (en) | Multivalent ligands which modulate angiogenesis | |
CN110845603A (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN105916877A (zh) | 长效胰岛素及其用途 | |
KR102494646B1 (ko) | 안정화된 피브로넥틴 기반 스캐폴드 분자 | |
Yamazaki et al. | Collagen-like cell-penetrating peptides. | |
IL222515A (en) | A mutant human albumin containing unnatural amino acids | |
JP2006517400A (ja) | シアノビリン変異体−ポリマー接合体 | |
CN113186109A (zh) | 一种酿酒酵母表达长效重组纤连蛋白及其在化妆品中的应用 | |
WO2005026375A3 (en) | Recombinant carrier molecule for expression, delivery and purification of target polypeptides | |
DE602005025141D1 (de) | In Zellen eindringende Peptide als Träger für Moleküle | |
JPWO2016136708A1 (ja) | 膜透過性ペプチドを側鎖に有する高分子化合物 | |
JP2008518622A5 (ru) | ||
CN116925240A (zh) | 一种重组胶原蛋白及其表达方法和应用 | |
CN112500495A (zh) | 一种elp-ⅲ型胶原蛋白的纯化方法及应用 | |
US20130237476A1 (en) | Adipose tissue targeted peptides | |
JP6982395B2 (ja) | インターロイキン10の産生量増加剤 | |
JP2011030453A (ja) | 細胞の生産方法 | |
US11648279B2 (en) | Composition for cell transplant, and method for cell transplant | |
WO2007068053A1 (en) | Recombinant protein production | |
CN103980366B (zh) | 一种白介素融合蛋白及其制备方法和应用 | |
US11661439B2 (en) | Peptide hydrogels and use thereof | |
JP2009538150A (ja) | Peg修飾されたアルギニン/リシンオキシドレダクターゼ | |
JP5673596B2 (ja) | 細胞膜透過性を有する製剤及び細胞膜透過性組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20141209 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190412 |